Your support fuels our research to #EndALS! Donate Now


TDI 201

This PERK inhibitor is being explored by scientists at the ALS Therapy Development Institute for its ability to modulate the efficacy of the UPR pathway, thereby protecting against neurotoxicity found to play a role in ALS.


Type: Small Molecule
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

We are in the process of analyzing data produced from a rigorous preclinical survival efficacy study on this small molecule.

Comment on this Topic

(All comments are moderated before they appear here.)